binance digital currency, Block

Ministry of National Defense: Fujian Ship will gradually launch the follow-up test project. On the morning of December 13th, Senior Colonel Wu Qian, director of the Information Bureau of the Ministry of National Defense and spokesman of the Ministry of National Defense, released a message on the recent military-related issues. Reporter: According to the announcement of Shanghai Maritime Safety Administration, in early December, traffic control was implemented for the import of a large ship in the deep water channel of the Yangtze River estuary. Some analysts believe that China Navy Fujian Ship may have completed its fifth sea trial and returned to its home port. Can you confirm it? Wu Qian: It is a normal arrangement for Fujian Ship to carry out relevant tests during the construction process. In the next step, follow-up test projects will be gradually launched according to the progress of aircraft carrier construction. (issued by the Ministry of National Defense)Meta released a new AI tool, which can enhance the experience of the Meta-universe. On Thursday, the American technology giant Meta said that it would release an artificial intelligence model called Meta Motivo, which can control the actions of a digital agent similar to human beings and may enhance the experience of the meta-universe. According to the company, Meta Motivo solves the common body control problems in digital avatars, enabling them to exercise in a more realistic and human-like way. "We believe that this research can pave the way for a fully concrete agent in the meta-universe, resulting in a more realistic NPC (non-player character), democratization of character animation, and a new immersive experience."Onlikon: The cooperative product Aidit calcitonin soft capsules is planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13th, and on December 12th, the company received a notice from its partner Beijing Meifurun Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Meifurun") that the Aidit calcitonin soft capsules jointly developed by the company and its wholly-owned subsidiary Wenzhou Haihe Pharmaceutical Co., Ltd. are planned to be selected for the tenth batch of national centralized drug procurement. According to the Pharmaceutical Cooperation Agreement signed by the company and its partner Mei Furun, the company owns 50% of the cooperative products.

Guotai Junan: It is suggested that the beauty care sector with product and channel changes and flexibility should be optimized from the bottom up. Guotai Junan said that after the pressure of consumption in 2022 and the destocking of consumers in 2023, the beauty consumption will return to the normal purchase cycle in 2024, and the industry prosperity will improve month-on-month, and the double-digit growth of online beauty will be achieved. However, after the channel dividend subsided, the platform traffic and price competition became fierce, and the brand differentiation further intensified. Relying on the product innovation and channel operation ability brought by organizational efficiency, the performance of domestic products in the head is still bright, and the rise of new domestic products has spread from beauty cosmetics to personal care. Looking forward to 2025, the market risk appetite will be significantly restored. Because of its many changes and the rising trend of domestic products as a whole, the American nursing sector has obvious growth attributes and significantly benefited from its style. Brand differentiation in the fundamental dimension has intensified, and it is suggested that the flexible target with product and channel changes should be optimized from bottom to top.After the release of the Bank of Japan's short-term report, the yen rose slightly.Yingsi Intelligent announced that it had received a milestone payment of $10 million from Exelixis. On December 13th, Yingsi Intelligent, a biomedical technology company, announced that based on the progress made in the clinical stage of XL309(ISM3091) project, the company had recently received the first clinical milestone payment from Exelixis, with a total amount of $10 million.

The moderate increase in inflation in the United States consolidated the expectation of interest rate cuts in December. According to the data released by the US Department of Labor on December 11, local time, the US consumer price index (CPI) increased by 0.3% in November, an increase of 0.1 percentage point over October. Inflation continues to rise moderately, which is in line with the market's previous judgment and also supports the expectation that the Fed will continue to cut interest rates this month. However, considering the slowdown in inflation and the increase in uncertainties affecting the economy, many analysts believe that the Fed may slow down the pace of interest rate cuts in the future. (Economic Information Daily)This year's performance is the worst since the epidemic, and Starbucks will reduce the salary increase for its employees. An internal document shows that in view of the company's worst financial performance since the epidemic, Starbucks will reduce the salary increase for its coffee shop employees. According to different qualifications, this year's salary increase is generally between 2% and 3%, while last year's salary increase was at least 3%, and employees who have served for five years or more were at least 5%. The salary increase will take effect on December 30, and employees will see the change of payroll on January 10 or January 17.Citic Jiantou Pharmaceutical's 2025 strategy: looking for new additions and integration opportunities. Citic Jiantou said that looking forward to 2025, the reform policy in the medical field has been normalized, and the most noteworthy incremental policy in the medical insurance field is to establish a diversified payment system. The medical field is about to usher in the reform of "deep water areas" such as salary system and graded diagnosis and treatment, which is in line with expectations as a whole. At the same time, the innovation of China's pharmaceutical industry has gradually stepped onto the international stage, some sub-sectors will be marginally improved, and industry integration will begin. We are optimistic about the investment opportunities in the pharmaceutical industry in 2025. It is suggested to focus on the new increase (innovation, going out to sea, marginal change) and industry integration opportunities.